Kyverna Therapeutics (KYTX) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Kyverna Therapeutics (NASDAQ: KYTX) recently:

• 12/29/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Kyverna Therapeutics had its price target raised by analysts at Wells Fargo & Company from $31.00 to $33.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Kyverna Therapeutics was given a new $33.00 price target on by analysts at Morgan Stanley.
• 12/15/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Kyverna Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/8/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Kyverna Therapeutics had its price target raised by analysts at Morgan Stanley from $20.00 to $25.00. They now have an “overweight” rating on the stock.
• 12/1/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/5/2025 – Kyverna Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other Kyverna Therapeutics news, major shareholder Biopartners Opportuni Westlake purchased 133,333 shares of Kyverna Therapeutics stock in a transaction on Thursday, December 18th. The shares were bought at an average price of $7.50 per share, with a total value of $999,997.50. Following the purchase, the insider directly owned 869,317 shares in the company, valued at $6,519,877.50. This trade represents a 18.12% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Karen Marie Walker sold 23,998 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $12.20, for a total transaction of $292,775.60. Following the completion of the sale, the chief technology officer directly owned 22,636 shares of the company’s stock, valued at $276,159.20. The trade was a 51.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 22.00% of the stock is currently owned by corporate insiders.

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.